Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00798-9, but it redirected us to https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00798-9. The analysis below is for the second page.

Title[redir]:
Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy | Cell Communication and Signaling | Full Text
Description:
Background Research is revealing the complex coordination between cell signaling systems as they adapt to genetic and epigenetic changes. Tools to uncover these highly complex functional linkages will play an important role in advancing more efficacious disease treatments. Current tumor cell signal transduction research is identifying coordination between receptor types, receptor families, and transduction pathways to maintain tumor cell viability despite challenging tumor microenvironment conditions. Methods In this report, coactivated abnormal levels of signaling activity for c-Met and HER family receptors in live tumor cells were measured by a new clinical test to identify a subpopulation of breast cancer patients that could be responsive to combined targeted therapies. The CELsignia Multi-Pathway Signaling Function (CELsignia) Test uses an impedance biosensor to quantify an individual patient’s ex vivo live tumor cell signaling response in real-time to specific HER family and c-Met co-stimulation and targeted therapies. Results The test identified breast tumors with hyperactive HER1, HER2, HER3/4, and c-Met coordinated signaling that express otherwise normal amounts of these receptors. The supporting data of the pre-clinical verification of this test included analyses of 79 breast cancer patients’ cell response to HER and c-Met agonists. The signaling results were confirmed using clinically approved matching targeted drugs, and combinations of targeted drugs in addition to correlative mouse xenograft tumor response to HER and c-Met targeted therapies. Conclusions The results of this study demonstrated the potential benefit of a functional test for identifying a subpopulation of breast cancer patients with coordinated abnormal HER and c-Met signaling for a clinical trial testing combination targeted therapy. Video Abstract

Matching Content Categories {📚}

  • Education
  • Science
  • Telecommunications

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🚄 Respectable Traffic: 10k - 20k visitors per month


Based on our best estimate, this website will receive around 10,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure how the site profits.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cmet, signaling, cell, test, cells, pubmed, cancer, celsignia, tumor, receptor, article, patient, combination, google, scholar, fig, breast, patients, data, growth, factor, inhibitors, drug, cas, panher, neratinib, hgf, tepotinib, table, analysis, treatment, targeted, antagonists, egf, size, hcc, central, clinical, response, signal, study, obtained, receptors, effects, abnormal, family, live, drugs, agonists, full,

Topics {✒️}

anti-hgf-c-met-ax488 blocks c-met-dependent signaling full size image multi-dimensional signaling features monoclonal anti-her2 antibody adhesion complex-regulated adhesion/migration c-met-targeting therapeutics cabozantinib c-met pathway factor live/dead fixable dye c-met signaling score live-cell celsignia assay cg-prkdcscid il2rgtm1wjl/szj /c-met dysfunctional signal intracellular phospho-flow cytometry local intra-cellular organization mmtv-wnt1-driven basal her2-negative breast cancers involved c-met cancer c-met signaling scores c-met coordinated signaling c-met receptor signaling apoptotic marker phosphatidyl-serine met/hgf pathway activation exponential log-scale fit c-met-targeted therapy c-met signaling activity aberrant c-met activation c-met signaling dysfunction her1 + c-met antagonist combination abnormal c-met signaling return’ canonical bio-correlates sensitivity/false positive pair c-met signaling pathways activated c-met signals representative dose–response curve predicting ligand-dependent tumors applying c-met inhibitors bmc cancer c-met receptor antagonists hyperactive c-met signaling c-met targeted drug drug-induced cell stress c-met expression level single-cell type level c-met inhibitors caused c-met targeted therapies c-met inhibitor-sensitive detectable dose-dependent effect c-met inhibitors identified c-met targeted drugs

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
         description:Research is revealing the complex coordination between cell signaling systems as they adapt to genetic and epigenetic changes. Tools to uncover these highly complex functional linkages will play an important role in advancing more efficacious disease treatments. Current tumor cell signal transduction research is identifying coordination between receptor types, receptor families, and transduction pathways to maintain tumor cell viability despite challenging tumor microenvironment conditions. In this report, coactivated abnormal levels of signaling activity for c-Met and HER family receptors in live tumor cells were measured by a new clinical test to identify a subpopulation of breast cancer patients that could be responsive to combined targeted therapies. The CELsignia Multi-Pathway Signaling Function (CELsignia) Test uses an impedance biosensor to quantify an individual patient’s ex vivo live tumor cell signaling response in real-time to specific HER family and c-Met co-stimulation and targeted therapies. The test identified breast tumors with hyperactive HER1, HER2, HER3/4, and c-Met coordinated signaling that express otherwise normal amounts of these receptors. The supporting data of the pre-clinical verification of this test included analyses of 79 breast cancer patients’ cell response to HER and c-Met agonists. The signaling results were confirmed using clinically approved matching targeted drugs, and combinations of targeted drugs in addition to correlative mouse xenograft tumor response to HER and c-Met targeted therapies. The results of this study demonstrated the potential benefit of a functional test for identifying a subpopulation of breast cancer patients with coordinated abnormal HER and c-Met signaling for a clinical trial testing combination targeted therapy.
         datePublished:2022-01-08T00:00:00Z
         dateModified:2022-01-08T00:00:00Z
         pageStart:1
         pageEnd:17
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12964-021-00798-9
         keywords:
            HER
            c-Met
            Combination targeted therapy
            Dysfunctional signaling
            Cell Biology
            Protein-Ligand Interactions
            Receptors
            Cytokines and Growth Factors
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig8_HTML.png
         isPartOf:
            name:Cell Communication and Signaling
            issn:
               1478-811X
            volumeNumber:20
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ian A. MacNeil
               affiliation:
                     name:Celcuity, Inc.
                     address:
                        name:Celcuity, Inc., Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Salmaan A. Khan
               affiliation:
                     name:Celcuity, Inc.
                     address:
                        name:Celcuity, Inc., Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Adrish Sen
               affiliation:
                     name:Celcuity, Inc.
                     address:
                        name:Celcuity, Inc., Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sajjad M. Soltani
               affiliation:
                     name:Celcuity, Inc.
                     address:
                        name:Celcuity, Inc., Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David J. Burns
               affiliation:
                     name:Celcuity, Inc.
                     address:
                        name:Celcuity, Inc., Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brian F. Sullivan
               affiliation:
                     name:Celcuity, Inc.
                     address:
                        name:Celcuity, Inc., Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lance G. Laing
               url:http://orcid.org/0000-0003-4593-0685
               affiliation:
                     name:Celcuity, Inc.
                     address:
                        name:Celcuity, Inc., Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
      description:Research is revealing the complex coordination between cell signaling systems as they adapt to genetic and epigenetic changes. Tools to uncover these highly complex functional linkages will play an important role in advancing more efficacious disease treatments. Current tumor cell signal transduction research is identifying coordination between receptor types, receptor families, and transduction pathways to maintain tumor cell viability despite challenging tumor microenvironment conditions. In this report, coactivated abnormal levels of signaling activity for c-Met and HER family receptors in live tumor cells were measured by a new clinical test to identify a subpopulation of breast cancer patients that could be responsive to combined targeted therapies. The CELsignia Multi-Pathway Signaling Function (CELsignia) Test uses an impedance biosensor to quantify an individual patient’s ex vivo live tumor cell signaling response in real-time to specific HER family and c-Met co-stimulation and targeted therapies. The test identified breast tumors with hyperactive HER1, HER2, HER3/4, and c-Met coordinated signaling that express otherwise normal amounts of these receptors. The supporting data of the pre-clinical verification of this test included analyses of 79 breast cancer patients’ cell response to HER and c-Met agonists. The signaling results were confirmed using clinically approved matching targeted drugs, and combinations of targeted drugs in addition to correlative mouse xenograft tumor response to HER and c-Met targeted therapies. The results of this study demonstrated the potential benefit of a functional test for identifying a subpopulation of breast cancer patients with coordinated abnormal HER and c-Met signaling for a clinical trial testing combination targeted therapy.
      datePublished:2022-01-08T00:00:00Z
      dateModified:2022-01-08T00:00:00Z
      pageStart:1
      pageEnd:17
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12964-021-00798-9
      keywords:
         HER
         c-Met
         Combination targeted therapy
         Dysfunctional signaling
         Cell Biology
         Protein-Ligand Interactions
         Receptors
         Cytokines and Growth Factors
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12964-021-00798-9/MediaObjects/12964_2021_798_Fig8_HTML.png
      isPartOf:
         name:Cell Communication and Signaling
         issn:
            1478-811X
         volumeNumber:20
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ian A. MacNeil
            affiliation:
                  name:Celcuity, Inc.
                  address:
                     name:Celcuity, Inc., Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Salmaan A. Khan
            affiliation:
                  name:Celcuity, Inc.
                  address:
                     name:Celcuity, Inc., Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Adrish Sen
            affiliation:
                  name:Celcuity, Inc.
                  address:
                     name:Celcuity, Inc., Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sajjad M. Soltani
            affiliation:
                  name:Celcuity, Inc.
                  address:
                     name:Celcuity, Inc., Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David J. Burns
            affiliation:
                  name:Celcuity, Inc.
                  address:
                     name:Celcuity, Inc., Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brian F. Sullivan
            affiliation:
                  name:Celcuity, Inc.
                  address:
                     name:Celcuity, Inc., Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lance G. Laing
            url:http://orcid.org/0000-0003-4593-0685
            affiliation:
                  name:Celcuity, Inc.
                  address:
                     name:Celcuity, Inc., Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cell Communication and Signaling
      issn:
         1478-811X
      volumeNumber:20
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Celcuity, Inc.
      address:
         name:Celcuity, Inc., Minneapolis, USA
         type:PostalAddress
      name:Celcuity, Inc.
      address:
         name:Celcuity, Inc., Minneapolis, USA
         type:PostalAddress
      name:Celcuity, Inc.
      address:
         name:Celcuity, Inc., Minneapolis, USA
         type:PostalAddress
      name:Celcuity, Inc.
      address:
         name:Celcuity, Inc., Minneapolis, USA
         type:PostalAddress
      name:Celcuity, Inc.
      address:
         name:Celcuity, Inc., Minneapolis, USA
         type:PostalAddress
      name:Celcuity, Inc.
      address:
         name:Celcuity, Inc., Minneapolis, USA
         type:PostalAddress
      name:Celcuity, Inc.
      address:
         name:Celcuity, Inc., Minneapolis, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ian A. MacNeil
      affiliation:
            name:Celcuity, Inc.
            address:
               name:Celcuity, Inc., Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Salmaan A. Khan
      affiliation:
            name:Celcuity, Inc.
            address:
               name:Celcuity, Inc., Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Adrish Sen
      affiliation:
            name:Celcuity, Inc.
            address:
               name:Celcuity, Inc., Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Sajjad M. Soltani
      affiliation:
            name:Celcuity, Inc.
            address:
               name:Celcuity, Inc., Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:David J. Burns
      affiliation:
            name:Celcuity, Inc.
            address:
               name:Celcuity, Inc., Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Brian F. Sullivan
      affiliation:
            name:Celcuity, Inc.
            address:
               name:Celcuity, Inc., Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Lance G. Laing
      url:http://orcid.org/0000-0003-4593-0685
      affiliation:
            name:Celcuity, Inc.
            address:
               name:Celcuity, Inc., Minneapolis, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Celcuity, Inc., Minneapolis, USA
      name:Celcuity, Inc., Minneapolis, USA
      name:Celcuity, Inc., Minneapolis, USA
      name:Celcuity, Inc., Minneapolis, USA
      name:Celcuity, Inc., Minneapolis, USA
      name:Celcuity, Inc., Minneapolis, USA
      name:Celcuity, Inc., Minneapolis, USA

Social Networks {👍}(2)

External Links {🔗}(319)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Video.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref
  • Net/play">

Video Abstract

Background

The concept of coordinated c-Met (or hepatocyte growth factor receptor) and human epidermal growth factor receptor (HER) tyrosine kinase family signaling in cancer progression is well-established [5.32s.